MedPath

Patient preference based phosphate binder therapy

Conditions
Chronic Kidney Disease, end-stage renal disease
Registration Number
NL-OMON25073
Lead Sponsor
Amsterdam UMC, location VUmc
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
40
Inclusion Criteria

Age = 18 years
-Haemodialysis patients (since at least 3 months)
-Necessity of phosphate binding therapy
-Written informed consent

Exclusion Criteria

-Intolerance to one of three types of phosphate binders
-Expected cessation of dialysis treatment within 6 months

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Patient satisfaction with phosphate treatment measured with the Treatment Satisfaction Questionnaire for Medication (TSQM, version II).
Secondary Outcome Measures
NameTimeMethod
Quality of life (SF-12), dialysis symptoms index (DSI), number of treatment switches, plasma phosphate , drug side effects questionnaire, drug adherence, serum PTH and Alkaline phosphatase.
© Copyright 2025. All Rights Reserved by MedPath